Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of adjunctive zonisamide in primary generalized tonic-clonic seizures
2007-006695-10Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zonisamide in idiopathic epilepsy (IGE) and generalized tonic-clonic seizure (GTCS), sponsored by Eisai Co., Ltd. Primary endpoints: Long-term safety of zonisamide and Long-term maintenance of efficacy. Started Aug 2008; status: terminated.
02
Drugs
zonisamide
03
Conditions
idiopathic epilepsy (IGE)generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2007-006695-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006695-10.